Biogen Newsroom

Biogen's Strategic Acquisitions and Growth Potential: An Analyst's Hold Rating Justification

TipRanksJul 16 07:06 ET

Goldman Sachs Adjusts Price Target on Biogen to $342 From $340, Maintains Buy Rating

MT NewswiresJul 16 06:25 ET

Biogen Analyst Ratings

BenzingaJul 12 08:24 ET

Piper Sandler Adjusts Biogen's Price Target to $313 From $335, Keeps Overweight Rating

MT NewswiresJul 12 05:59 ET

Morgan Stanley Adjusts Price Target on Biogen to $311 From $331

MT NewswiresJul 11 08:34 ET

Barclays Remains a Hold on Biogen (BIIB)

TipRanksJul 10 05:01 ET

RBC Cuts Price Target on Biogen to $303 From $317, Keeps Outperform Rating

MT NewswiresJul 9 07:33 ET

Biogen Analyst Ratings

BenzingaJun 26 11:08 ET

Wedbush Adjusts Price Target on Biogen to $215 From $219

MT NewswiresJun 6 07:12 ET

Biogen Analyst Ratings

BenzingaJun 5 10:37 ET

Analysts' Opinions Are Mixed on These Healthcare Stocks: Gilead Sciences (GILD), Biogen (BIIB) and Argenx Se (ARGX)

TipRanksMay 30 23:04 ET

Biogen Analyst Ratings

BenzingaMay 29 10:02 ET

RBC Capital Sticks to Its Buy Rating for Biogen (BIIB)

TipRanksMay 29 06:48 ET

Analysts Offer Insights on Healthcare Companies: Inari Medical (NARI), Biogen (BIIB) and SOPHiA GENETICS (SOPH)

TipRanksMay 28 06:54 ET

Biogen's Strategic Diversification and Financial Strategy Garner Outperform Rating

TipRanksMay 24 01:55 ET

Strategic Acquisitions and Clinical Catalysts Bolster Biogen's Buy Rating

TipRanksMay 24 01:50 ET

Biogen (BIIB) Gets a Buy From Oppenheimer

TipRanksMay 23 08:00 ET

Analysts' Opinions Are Mixed on These Healthcare Stocks: Biogen (BIIB) and Incyte (INCY)

TipRanksMay 23 07:15 ET

Biogen Analyst Ratings

BenzingaMay 23 06:11 ET

Wedbush Raises Biogen Price Target to $219 From $215, Maintains Neutral Rating

MT NewswiresMay 22 09:50 ET